Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 13, 2024

SELL
$22.97 - $30.58 $450,717 - $600,040
-19,622 Reduced 33.2%
39,476 $1.07 Million
Q3 2023

Nov 14, 2023

SELL
$22.72 - $31.49 $2 Million - $2.77 Million
-88,033 Reduced 59.83%
59,098 $1.44 Million
Q2 2023

Aug 10, 2023

BUY
$25.3 - $39.67 $480,700 - $753,730
19,000 Added 14.83%
147,131 $4.09 Million
Q1 2023

May 12, 2023

BUY
$30.21 - $48.1 $1.17 Million - $1.87 Million
38,800 Added 43.43%
128,131 $4.27 Million
Q4 2022

Feb 10, 2023

SELL
$22.28 - $38.71 $458,968 - $797,426
-20,600 Reduced 18.74%
89,331 $2.75 Million
Q3 2022

Nov 01, 2022

BUY
$34.2 - $51.69 $3.76 Million - $5.68 Million
109,931 New
109,931 $3.75 Million
Q2 2022

Aug 09, 2022

BUY
$23.14 - $49.68 $643,292 - $1.38 Million
27,800 Added 36.56%
103,831 $3.6 Million
Q1 2022

May 12, 2022

SELL
$27.77 - $64.4 $286,031 - $663,320
-10,300 Reduced 11.93%
76,031 $3.48 Million
Q4 2021

Feb 14, 2022

BUY
$54.9 - $105.21 $885,646 - $1.7 Million
16,132 Added 22.98%
86,331 $5.41 Million
Q3 2021

Nov 15, 2021

BUY
$105.0 - $178.37 $390,285 - $663,001
3,717 Added 5.59%
70,199 $7.44 Million
Q2 2021

Aug 11, 2021

BUY
$125.11 - $180.0 $1.74 Million - $2.5 Million
13,900 Added 26.43%
66,482 $11.8 Million
Q1 2021

May 17, 2021

BUY
$126.27 - $191.71 $492,453 - $747,669
3,900 Added 8.01%
52,582 $6.98 Million
Q4 2020

Feb 16, 2021

BUY
$81.94 - $135.34 $270,402 - $446,622
3,300 Added 7.27%
48,682 $6.56 Million
Q3 2020

Nov 13, 2020

BUY
$73.3 - $89.48 $527,760 - $644,256
7,200 Added 18.86%
45,382 $3.77 Million
Q2 2020

Aug 17, 2020

BUY
$48.82 - $82.53 $375,914 - $635,481
7,700 Added 25.26%
38,182 $3.13 Million
Q1 2020

May 14, 2020

BUY
$39.1 - $62.9 $1.19 Million - $1.92 Million
30,482 New
30,482 $1.56 Million

Others Institutions Holding ZLAB

About Zai Lab Ltd


  • Ticker ZLAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,908,704
  • Market Cap $2.57B
  • Description
  • Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA f...
More about ZLAB
Track This Portfolio

Track Great West Life Assurance CO Portfolio

Follow Great West Life Assurance CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Great West Life Assurance CO , based on Form 13F filings with the SEC.

News

Stay updated on Great West Life Assurance CO with notifications on news.